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Ant i thrombot ic  and hemodynamic properties of molsidomine (0.10 mg/kg i.v.) were evaluated in an in-vivo 
model of coronary artery thrombosis initiated by electrical stimulation for 6 h. Molsidomine prolonged time to 
vessel occlusion and prevented heart  rate and end-diastolic pressure increase and contracti l i ty decrease. Infarct size 
was smaller after drug t reatment  related either to left ventricle (P < 0.02) or to vessel area-at-risk (P < 0.01). I t  is 
suggested that  molsidomine has ant i thrombotic  effects which might prevent acute coronary infarction. 
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I. Introduction 
Molsidomine is a new antianginal agent 
with effects on hemodynamics (Fiedler and 
Scholtholt, 1978) and on the venous side of 
the circulation (Holtz et al., 1978). In patients, 
the drug has been shown to be effective in the 
treatment of angina pectoris by a nitroglyce- 
rin-like mode of action but of substantially 
longer duration (Majid et al., 1980). Recent 
studies (Slany et al., 1981) in patients with 
coronary artery disease suggested that molsi- 
domine might decrease platelet reactivity as 
assessed by in-vitro aggregometry. The drug 
also produced a dilatation of large coronary 
vessels in the isolated blood perfused canine 
heart (Schaper, unpublished observations) 
which might serve as an important mechanism 
for improving coronary flow to an ischemic 
region of the myocardium via collateral ves- 
sels. The potential of molsidomine in this 
respect would be enhanced if the drug pre- 
vented in-vivo platelet aggregation in response 
to vascular injury. Accordingly, the present 
study was designed to determine the effects 
of molsidmone on protection of the acutely 
ischemic canine myocardium and on in-vivo 
platelet reactivity. 
2. Materials and methods  
14 adult mongrel dogs of either sex weighing 
between 18 to 26 kg were randomly assigned 
to groups receiving either molsidomine (8 
dogs) or saline (6 dogs), anesthetized with i.v. 
pentobarbital sodium (30 mg/kg), incubated 
and placed on positive pressure respiration 
(Harvard respirator, model 607) using room 
air. Body temperature was regulated at 37 +- 
1°C by a heating pad. Aortic blood pressure 
was measured by a cannula positioned in the 
descending aorta via the right femoral artery 
using a Statham pressure transducer (model 
P 23 Db). A peripheral vein was catheterized 
for compound administration. Left ventricular 
systolic and end<liastolic pressure was deter- 
mined by means of a microtip pressure trans- 
ducer (Millar Instr., model PC-350) introduced 
into the left ventricle via the exposed left 
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carotid artery. Heart rate was obtained from 
the electrocardiogram (limb lead II). Contrac- 
tility was obtained by continuous computer  
differentiation of  left ventricular pressure as 
clP/dt. The sum of  ST~egment elevations was 
obtained from 5 sLngle measurements at the 
determination times. A thoracotomy was per- 
formed at the fifth left intercostal space, the 
lungs retracted and the heart was suspended 
in a pericardial cradle. A calibrated flow 
probe was positioned around the left circum- 
flex coronary artery (LCX) distal to the 
atrial branch and proximal to its first descend- 
ing branch for measurement of  phasic and 
mean LCX flow by a f lowmeter (Carolina 
Instr.). Coronary vascular resistance was ob- 
tained by dividing mean aortic pressure by 
mean LCX flow. A silk snare was placed 
around the vessel distal to the probe. To aid 
in the insertion of  the LCX stimulating elec- 
trode, the tip of  a 25-gauge hypodermic 
needle was secured to the leading end of a 
28-gauge teflon coated silver wire (Romson 
et al., 1980b). This electrode was inserted 
through the wall of the LCX so that  the tip 
of  the electrode (2--3 mm) was in contact  
with the intimal lining of  the vessel. The 
circuit was completed by suturing a disc 
electrode to a subcutaneous region of  the 
chest wall. Hemodynamic variables were 
recorded on a Grass model 7 polygraph. 
2.1. Experimental design 
After basal hemodynamic measurements 
were recorded either molsidomine (0.10 mg/ 
kg) or saline were intravenously administered. 
15 to 20 min later (Holtz et al., 1978) electri- 
cal stimulation of the LCX was initiated at 
150 gA via the implanted silver wire electrode. 
Stimulation was continued for 6 h using a 
250 000 ~2 potentiometer ,  a 9 V nickel-- 
cadmium battery,  and a digital ammeter.  
Recordings were done every 15 min at 25 
mm/sec. 
2.2. Quantification of  infarct size and throm- 
bus weight 
Following final recordings at completion of 
the 6 h stimulation, the animal was sacrificed 
by an overdosage of  anesthetic, the heart was 
electrically fibrillated and rapidly removed for 
post-mortem quantification of  infarct size 
(Romson et al., 1980a). To this end, cannulae 
were inserted into the vessel distal to the site 
of  LCX occlusion and into the aortic root  
above the coronary ostia. The LCX coronary 
bed was perfused with 1.5% triphenyltetrazo- 
liumchloride (TTC) in 20 mM potassium phos- 
phate buffer. The aorta was perfused in a 
retrograde manner with 0.5% Evans blue. 
Both solutions were perfused at a constant 
pressure of 100 mmHg for 20 min. The heart 
was then sliced into 1.0-cm thick sections. 
The area of the left ventricle at risk was 
demarcated by lack of reddish staining of 
the tissue when perfused with TTC. The area- 
at-risk, in addition to the regions of  infracted 
myocardium were excised from the left ven- 
tricle and weighed. Thus, the extent  of infarc- 
tion was expressed as a percentage of  both 
total left ventricle and the area of myocardi- 
um at risk. The previously occluded LCX was 
dissected free of surrounding tissue and 
opened lengthwise. Adhering thrombotic  ma- 
terial was removed from the intimal surface 
of the LCX to determine thrombus wet 
weight. 
2.3. Statistical analysis 
Statistical analysis of  results on hemo- 
dynamics was made by use of Student 's  t-test 
for paired samples and analysis of variance 
followed by Dunnett 's  modification of the 
t-test. Infarct sizes were compared by use of 
the two-by-two chi square analysis. All data 
are expressed as mean -+ standard error of  the 
mean (S.E.M.). Differences between control 
and drug-treated values were considered signi- 
ficant when P < 0.05. 
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3. Results 
The results shown in table I summarize the 
effects of  molsidomine on myocardial hemo- 
dynamics during LCX stimulation. 30 rain 
after drug administration mean aortic pressure, 
left ventricular end-diastolic pressure, and 
mean LCX coronary blood flow decreased 
significantly. Heart rate and contractility (dP/ 
dtmax) remained unaffected by the drug. 
After occlusion of  the LCX, mean aortic 
pressure decreased in both  groups. In the 
saline group, heart  rate and end<liastolic 
pressure increased significantly while con- 
tractility fell. As a sign of  ischemia the sum of  
ST~egrnents elevated significantly in the 
saline controls until complet ion of the experi- 
ments, bu t  no changes occurred in the molsi- 
domine-treated group. LCX coronary blood 
flow fell to zero after 3.1 ± 0.4 h (table 2) of  
electrical stimulation in the  controls bu t  after 
3.8 ± 0.3 h in the molsidomine animals. Thus, 
TABLE 1 
Effec ts  o f  mol s idomine  on  myocardia l  hemodynamics .  
Parameter  C o m p o u n d  Cont ro l  30 min 3 h 4 h 6 h 
Mean aort ic  pressure M 121 81 118 97 118 
(mmHg)  + 5 b -- 4 C --+ 5 + 4 c + 4 
NaC1 118 117 119 93 116 
-+3 -+5 -+4 + 6  c -+3 
Hear rate  (rain -1 ) M 124 127 122 131 120 
• + 8  - + 1 0  + 8  -+9 -+11 
NaC1 131 130 129 169 126 
• + 9  -+9 -+7 + 7  -+9 
Lef t  ventr icular  M 6.8 3.2 3.8 6.5 7.2 
end-diastol ic  pressure + 1.2 -+ 0.7 c + 0.8 c -+ 1.1 -+ 1.2 
(mmHg)  NaCl 5.4 6.2 5.8 13.7 11.2 
-+ 0.9 -+ 0.5 -+ 0.7 -+ 1.2 c + 0.8 c 
DP/dtmax M 2 180 2 240 2 016 2 007 1 970 
(mmHg/sec )  -+ 201 -+ 199 -+ 167 -+ 137 -+ 211 
NaCl 2 431 2 601 2 379 1 421 1 640 
+ 186 -+ 201 -+ 154 -+ 141 c + 1 3 4  c 
ST-segment  e levat ion M 34 31 35 40 37 
(mV)  -+ 6 + 4 -+ 9 -+ 5 -+ 8 
NaC1 42 40 52 88 83 
• + 3  -+6 -+4 c + 4  d -+6 c 
Mean coronary  b lood  M 48.1 36.2 44.3 11.8 0 
f low (ml /min)  -+ 3.2 -+ 4.1 c -+ 2.2 -+ 1.5 d -+ 3.2 d 
NaC1 40.0 42.6 39.6 0 0 
• + 4 . 1  -+3.0 -+3.2 -+1.1 d -+0 d 
Coronary  resis tance M 2.5 2.2 2.7 - -  - -  
(mmHg × rain x m1-1) -+ 1.0 -+ 0.8 + 0.7 
NaCl 3.0 2.8 3.0 - -  - -  
+ 0.6 + 0.8 -+ 0.8 
a Minutes or hours after 0.10 mg/kg molsidomine (M) and saline (NaCI) administration. 
b Values are given as mean + S.E.M. of 8 experiments in the molsidomine and of 6 experiments in the saline 
group.  
e Significantly d i f fe ren t  vs. con t ro l  wi th  P < 0.05. 
d Significantly d i f fe ren t  vs. con t ro l  wi th  P < 0.01. 
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TABLE 2 
Effec ts  o f  mo l s idomine  on t h r o m b u s  fo rma t ion ,  
infarct  size, and t h r o m b u s  weight .  Data are given as 
the  mean  -+ S.E.M. o f  8 expe r imen t s  in the  molsido-  
mine  group and 6 expe r imen t s  in the  saline group.  
LCX = lef t  c i rcumflex  co ronary  ar tery .  
Parameter  . Saline Mols idomine  
T h r o m b u s  fo rma t ion  
(hours ,  a f ter  c o m p o u n d  
admin is t ra t ion)  3.1 -+ 0.4 3.8 -+ 0.3 a 
Infarc t  size : 
(1) % l e f t  centr icular  mass 28 -+ 2.0 14 + 3.0 b 
(2) % LCXarea-a t - r i sk  58 + 14 18 + 3.0 c 
LCX t h r o m b u s  mass 
(rag, we t  weight)  32 -+ 4.0 14 -+ 0.8 a 
a Signif icantly d i f fe ren t  vs. con t ro l  wi th  P < 0.05. 
b Signif icantly d i f fe ren t  vs. con t ro l  wi th  P < 0.02. 
c Signif icantly d i f fe ren t  vs. con t ro l  wi th  P < 0.01. 
coronary resistance did not  change in either 
group until the time of  vessel occlusion. The 
results shown in table 2 summarize the effects 
o f  molsidomine on infarct size and thrombus 
wet  weight. Compared to controls drug treat- 
ment  re.~ulted in significantly reduced ischemia 
when related to left ventricular weight or to 
the LCX area-at-risk. Drug-treatment also 
reduced development  of  LCX thrombus mass, 
and examination of  the vessel in molsidomine- 
treated animals revealed minor thrombus 
adherence and intima necrosis. 
4. Discussion 
The results presented in this report  demon- 
strate marked ant i thrombotic  properties of  
molsidomine in an in-vivo model  of  coronary 
artery thrombosis.  The model  simulates 
human coronary artery thrombus formation 
as intimal injury produced by  low amperage 
electrical stimulation of  the  LCX induced 
platelet adhesion and secondary recruitment 
of  platelets to form aggregates (Romson et 
al., 1980a) similar to morphology and compo- 
sition of  humen coronary artery thrombi.  
Although coronary blood flow decreased 
after administration of  molsidomine conco- 
mitant  to the fall in perfusion pressure, an 
improvement  of  coronary blood supply to 
jeopardized tissues can be assumed from the 
smaller ultimate ischemic regions. 
In recent experiments (Schaper, unpublished 
results) with canine hearts perfused at constant  
aortic pressure large epicardial coronary 
arteries dilated. Such an event may not  
increase coronary blood flow in the unaffected 
area of  the coronary bed bu t  it may serve as 
an important  mechanism for improving 
coronary flow to an ischemic region of the 
myocardium probably via collaterals. At the 
same time there is a dose<lependent decrease 
in blood pressure (Fiedler and Scholtholt,  
1978) which is not  accompanied by  reflex 
increase in heart rate or contractility. Thus, it 
seems likely that  a dilatation of  the coronary 
bed, as indicated in the present s tudy by a 
minor decrease in coronary resistance (table 
1) together with an increase in regional myo- 
cardial blood flow (Scholtholt  et al., 1978) 
and the fall in myocardial work and oxygen 
consumption (Gross and Gharaibeh, 1980) 
resulted in a significant protect ion of  the 
ischemic myocardium with respect to viability 
of  jeopardized tissues. The significance of  the 
present s tudy lies in the fact that  ischemic 
heart  disease represents one major health 
problem and is a leading cause of  death and 
morbidity.  Current therapy with agents such 
as nitrates, ~-adrenergic receptor  blocking 
agents, and slow calcium channel blocking 
drugs, although effective in a large percentage 
of  such patients, has not  been wi thout  dif- 
ficulty. Thus, the need for new drugs with 
mechanisms which compliment  the actions of  
existing agents by  additional mode  of  actions 
is very much in demand. The initial clinical 
trials with molsidomine suggested that it may 
be valuable for t reatment  of  the ischemic 
heart. In addition to the aforementioned 
hemodynamic,  extracardiac effects of  the 
drug and influences on regional myocardial 
b lood flow, there may be a direct effect  on 
platelet aggregation and thrombus forma- 
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t ion  in vivo which  prevents  c o r o n a r y  ar tery  
nar rowing and /o r  occlus ion as one  pr imary  
cause for  myocard ia l  ischemia. 
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